Immunovant, Inc. (IMVT)
- Previous Close
30.69 - Open
31.10 - Bid 33.58 x 100
- Ask 33.67 x 200
- Day's Range
31.05 - 33.69 - 52 Week Range
19.50 - 45.58 - Volume
1,968,673 - Avg. Volume
983,122 - Market Cap (intraday)
4.921B - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
-- - EPS (TTM)
-2.09 - Earnings Date Nov 7, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
48.62
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
immunovant.comRecent News: IMVT
View MoreResearch Reports: IMVT
View MorePerformance Overview: IMVT
Trailing total returns as of 9/5/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMVT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMVT
View MoreValuation Measures
Market Cap
4.92B
Enterprise Value
4.36B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
9.03
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-39.66%
Return on Equity (ttm)
-64.54%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-272.55M
Diluted EPS (ttm)
-2.09
Balance Sheet and Cash Flow
Total Cash (mrq)
560M
Total Debt/Equity (mrq)
0.01%
Levered Free Cash Flow (ttm)
-157.4M